Published 1 year ago

Roivant, Pfizer create unit for inflammatory disease drug

Summary by Ground News

Roivant Sciences and Pfizer announce creation of a new unit to develop RVT-3101. The drugmakers' treatment for ulcerative colitis will be developed in the new unit. The new unit will be called Roivant-Pfizer Ulcerative Colitis.

0 Articles

All

Left

Center

Right

Reuters

Roivant, Pfizer create unit for inflammatory disease drug

Roivant Sciences and Pfizer Inc on Thursday announced the launch of a unit to develop RVT-3101, the drugmakers' treatment for an inflammatory bowel disease. The drug's efficacy as a treatment for ulcerative colitis is currently being assessed in a mid-stage study. Under the terms, biotech firm Roivant will be responsible for funding the development and will retain commercialization

1 year ago·United Kingdom

Read Full Article

Globe Newswire

Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases

Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody that blocks tumor necrosis factor-like ligand 1A...

1 year ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.